{"id":514131,"date":"2021-07-16T10:03:15","date_gmt":"2021-07-16T14:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/"},"modified":"2021-07-16T10:03:15","modified_gmt":"2021-07-16T14:03:15","slug":"aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/","title":{"rendered":"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Work on Coronavirus, Influenza and Ebolavirus Advances<\/h2>\n<h2 class=\"xn-hedline\">Computer Aided Drug Design Accelerates Development<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">July 16, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0AIkido Pharma Inc. (Nasdaq: AIKI) (&#8220;AIkido&#8221; or the &#8220;Company&#8221;) today provided an update to the progress of its antiviral platform with the <span class=\"xn-org\">University of Maryland<\/span> School of Medicine.\u00a0 The Company stated:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg\" title=\"(PRNewsfoto\/AIkido Pharma Incorporated)\" alt=\"(PRNewsfoto\/AIkido Pharma Incorporated)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.\u00a0 Scientists have identified proteins that are required for viral replication in these viruses.\u00a0 Computers were also used to aid the drug design approach by identifying compounds that are predicted to block viral replication.\u00a0 From this work, scientists have identified 4 lead compounds that block Influenza, Coronavirus (CoV-2), and Ebolavirus replication.\u00a0 \u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Anthony Hayes<\/span>, CEO of AIkido Pharma stated, &#8220;Moving forward, the upcoming phase is to optimize the best of these compounds to make them even better.\u00a0 At the same time, the scientists will take the compounds and measure how well they are bioavailable in the lungs when given either as an injection or as an oral dosing.\u00a0 Ultimately the goal is to have compounds that demonstrate strong antiviral activity against Influenza virus, SARS-CoV-2, and Ebolavirus.\u00a0 These illnesses have significant unmet medical needs as demonstrated by their continued resurgence and represent tremendous market opportunities.&#8221;<\/p>\n<p>\n        <b>About AIkido Pharma Inc.<br \/><\/b>AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.\u00a0 The Company&#8217;s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The\u00a0University of <span class=\"xn-location\">Texas<\/span> at Austin\u00a0and\u00a0University of <span class=\"xn-location\">Maryland<\/span> at <span class=\"xn-location\">Baltimore<\/span>. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.\u00a0 The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.<\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>Certain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;intend&#8221; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company&#8217;s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<p>Investor Relations:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n<p id=\"indentid\" class=\"prnml40\">Hayden IR<br \/><span class=\"xn-person\">Brett Maas<\/span>, Managing Partner<br \/>Phone: (646) 536-7331<br \/>Email: <a target=\"_blank\" href=\"mailto:brett@haydenir.com\" rel=\"nofollow noopener\">brett@haydenir.com<\/a><br \/><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3229702-1&amp;h=3263723920&amp;u=http%3A%2F%2Fwww.haydenir.com%2F&amp;a=www.haydenir.com\" rel=\"nofollow noopener\">www.haydenir.com<\/a><\/p>\n<p>AIkido Pharma Inc.:\u00a0\u00a0\u00a0 <\/p>\n<p id=\"indentid\" class=\"prnml40\">Phone: 212-745-1373<br \/>Email: <a target=\"_blank\" href=\"mailto:investorrelations@aikidopharma.com\" rel=\"nofollow noopener\">investorrelations@aikidopharma.com<\/a><br \/><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3229702-1&amp;h=3798438316&amp;u=http%3A%2F%2Fwww.aikidopharma.com%2F&amp;a=www.aikidopharma.com\" rel=\"nofollow noopener\">www.aikidopharma.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY44941&amp;sd=2021-07-16\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland-301335312.html\">https:\/\/www.prnewswire.com\/news-releases\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland-301335312.html<\/a><\/p>\n<p>SOURCE  AIkido Pharma Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY44941&amp;Transmission_Id=202107161000PR_NEWS_USPR_____NY44941&amp;DateId=20210716\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Work on Coronavirus, Influenza and Ebolavirus Advances Computer Aided Drug Design Accelerates Development PR Newswire NEW YORK, July 16, 2021 \/PRNewswire\/ &#8212;\u00a0AIkido Pharma Inc. (Nasdaq: AIKI) (&#8220;AIkido&#8221; or the &#8220;Company&#8221;) today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine.\u00a0 The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.\u00a0 Scientists have identified proteins that are required for viral replication in these viruses.\u00a0 Computers were also used to aid the drug design approach by identifying compounds that are predicted to block viral replication.\u00a0 From this work, scientists have identified &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-514131","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Work on Coronavirus, Influenza and Ebolavirus Advances Computer Aided Drug Design Accelerates Development PR Newswire NEW YORK, July 16, 2021 \/PRNewswire\/ &#8212;\u00a0AIkido Pharma Inc. (Nasdaq: AIKI) (&#8220;AIkido&#8221; or the &#8220;Company&#8221;) today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine.\u00a0 The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.\u00a0 Scientists have identified proteins that are required for viral replication in these viruses.\u00a0 Computers were also used to aid the drug design approach by identifying compounds that are predicted to block viral replication.\u00a0 From this work, scientists have identified &hellip; Continue reading &quot;AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-16T14:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland\",\"datePublished\":\"2021-07-16T14:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/\"},\"wordCount\":566,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/\",\"name\":\"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"datePublished\":\"2021-07-16T14:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1138079\\\/Aikida_Pharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/","og_locale":"en_US","og_type":"article","og_title":"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland - Market Newsdesk","og_description":"Work on Coronavirus, Influenza and Ebolavirus Advances Computer Aided Drug Design Accelerates Development PR Newswire NEW YORK, July 16, 2021 \/PRNewswire\/ &#8212;\u00a0AIkido Pharma Inc. (Nasdaq: AIKI) (&#8220;AIkido&#8221; or the &#8220;Company&#8221;) today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine.\u00a0 The Company stated: The goal for the project is the identification and optimization of anti-viral compounds that inhibit viral replication by targeting a protein complex that degrades RNA at the cellular level.\u00a0 Scientists have identified proteins that are required for viral replication in these viruses.\u00a0 Computers were also used to aid the drug design approach by identifying compounds that are predicted to block viral replication.\u00a0 From this work, scientists have identified &hellip; Continue reading \"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-16T14:03:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland","datePublished":"2021-07-16T14:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/"},"wordCount":566,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/","name":"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","datePublished":"2021-07-16T14:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1138079\/Aikida_Pharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aikido-pharma-issues-update-on-antiviral-platform-with-the-university-of-maryland\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=514131"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514131\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=514131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=514131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=514131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}